Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 20:13:983403.
doi: 10.3389/fmicb.2022.983403. eCollection 2022.

Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies

Affiliations
Review

Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies

Marcelo B Sztein et al. Front Microbiol. .

Abstract

Enteric infectious diseases account for more than a billion disease episodes yearly worldwide resulting in approximately 2 million deaths, with children under 5 years old and the elderly being disproportionally affected. Enteric pathogens comprise viruses, parasites, and bacteria; the latter including pathogens such as Salmonella [typhoidal (TS) and non-typhoidal (nTS)], cholera, Shigella and multiple pathotypes of Escherichia coli (E. coli). In addition, multi-drug resistant and extensively drug-resistant (XDR) strains (e.g., S. Typhi H58 strain) of enteric bacteria are emerging; thus, renewed efforts to tackle enteric diseases are required. Many of these entero-pathogens could be controlled by oral or parenteral vaccines; however, development of new, effective vaccines has been hampered by lack of known immunological correlates of protection (CoP) and limited knowledge of the factors contributing to protective responses. To fully comprehend the human response to enteric infections, an invaluable tool that has recently re-emerged is the use of controlled human infection models (CHIMs) in which participants are challenged with virulent wild-type (wt) organisms. CHIMs have the potential to uncover immune mechanisms and identify CoP to enteric pathogens, as well as to evaluate the efficacy of therapeutics and vaccines in humans. CHIMs have been used to provide invaluable insights in the pathogenesis, host-pathogen interaction and evaluation of vaccines. Recently, several Oxford typhoid CHIM studies have been performed to assess the role of multiple cell types (B cells, CD8+ T, Tregs, MAIT, Monocytes and DC) during S. Typhi infection. One of the key messages that emerged from these studies is that baseline antigen-specific responses are important in that they can correlate with clinical outcomes. Additionally, volunteers who develop typhoid disease (TD) exhibit higher levels and more activated cell types (e.g., DC and monocytes) which are nevertheless defective in discrete signaling pathways. Future critical aspects of this research will involve the study of immune responses to enteric infections at the site of entry, i.e., the intestinal mucosa. This review will describe our current knowledge of immunity to enteric fevers caused by S. Typhi and S. Paratyphi A, with emphasis on the contributions of CHIMs to uncover the complex immunological responses to these organisms and provide insights into the determinants of protective immunity.

Keywords: challenge human infection model; correlates of protection; enteric diseases; immunity; typhoid; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic of a typhoid control human infection model (CHIM). Volunteers were recruited and challenged on day 0 with wt S. Typhi (Quailes Strain) at either of two doses (low—103 CFU or high—104 CFU). At around day 7, some of volunteers developed typhoid disease (TD) while others did not develop typhoid disease (NoTD). On day 14, all volunteers (TD and NoTD) received antibiotics (Abx). PBMC were collected from multiple time points from baseline up to 360 days after challenge.
Figure 2
Figure 2
Characteristics of monocytes and dendritic cells (DC) in a typhoid CHIM. Summary of responses by monocytes and DC reported in Toapanta et al. (2015) and including comparisons between TD and NoTD at baseline (before challenge), early days after challenge (D1-9) and at later time points after challenge (D14-28). ↑: Increase; ↓: Decrease; ↔: No difference.
Figure 3
Figure 3
Characteristics of B cells in a typhoid CHIM. Summary of S. Typhi-specific B cell responses reported in Toapanta et al. (2016) including comparisons between TD and NoTD at baseline (before challenge), early days after challenge (D1-9) and at later time points after challenge (D14-28). ↑: Increase; ↓: Decrease; ↔: No difference.
Figure 4
Figure 4
Memory CD8+ T cells responses in a typhoid CHIM. Summary of S. Typhi-specific CD8+ T memory cell responses reported by Fresnay et al. (2016, , including comparisons between TD and NoTD at baseline (before challenge), early days after challenge (D1-9) and at later time points after challenge (D14-28) with either of two doses of wt S. Typhi (Low: 103 CFU and high: 104 CFU). ↑: Increase; ↓: Decrease; ↔: No difference.
Figure 5
Figure 5
Characteristics of regulatory T cells (Tregs) in a typhoid CHIM. Summary of S. Typhi-specific Tregs responses reported by McArthur et al. (2015) including comparisons between TD and NoTD at baseline (before challenge), early days after challenge (D1-9) and at later time points after challenge (D14-28). ↑: Increase; ↓: Decrease; ↔: No difference.
Figure 6
Figure 6
Characteristics of MAIT cells in a typhoid CHIM. Summary of MAIT cell responses reported by Salerno-Goncalves et al. (2010, including comparisons between TD and NoTD at baseline (before challenge), early days after challenge (D1-9) and at later time points after challenge (D14-28) with either of two doses of wt S. Typhi (Low: 103 CFU and high: 104 CFU). ↑: Increase; ↓: Decrease; ↔: No difference.

References

    1. Aandahl E. M., Michaelsson J., Moretto W. J., Hecht F. M., Nixon D. F. (2004). Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78, 2454–2459. doi: 10.1128/JVI.78.5.2454-2459.2004, PMID: - DOI - PMC - PubMed
    1. Bambery B., Selgelid M., Weijer C., Savulescu J., Pollard A. J. (2016). Ethical criteria for human challenge studies in infectious diseases. Public Health Ethics 9, 92–103. doi: 10.1093/phe/phv026, PMID: - DOI - PMC - PubMed
    1. Betts M. R., Brenchley J. M., Price D. A., De Rosa S. C., Douek D. C., Roederer M., et al. . (2003). Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65–78. doi: 10.1016/S0022-1759(03)00265-5, PMID: - DOI - PubMed
    1. Betts M. R., Gray C. M., Cox J. H., Ferrari G. (2006). Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev. Vaccines 5, 505–516. doi: 10.1586/14760584.5.4.505, PMID: - DOI - PubMed
    1. Bhutta Z. A., Threlfall J. (2009). Addressing the global disease burden of typhoid fever. JAMA 302, 898–899. doi: 10.1001/jama.2009.1259, PMID: - DOI - PubMed